热门资讯> 正文

赛诺菲获得欧盟对Scarlisa皮下版本的批准建议

2026-03-27 22:56

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of a subcutaneous formulation of Sanofi's (SNY) Scarlisa (isatuximab) administered via on-body injection.
If approved, Scarlisa would become the only oncologic approved in the EU via an on-body injection.
Scarlisa is approved for multiple myeloma.

More on Sanofi

Dupixent's Impact On Sanofi: A Quantitative Projection Of Its Revenue
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi replaces CEO Paul Hudson, names Belén Garijo as successor
Sanofi anticipates profitable growth to continue over at least five years

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。